Recent Updates — KMDA
Kamada Ltd. announced the commercial launch of two new biosimilar products in Israel: Ustekinumab-Kamada (a biosimilar to Stelara) and Enoxaparin-Kamada (a biosimilar to Clexane). These additions bring Kamada's total marketed biosimilars in the region to four, joining Bevacizumab-Kamada and Pegfilgrastim-Kamada. The company expects its existing commercial portfolio of biosimilars to generate approximately $4 million in sales in 2026, growing to roughly $10 million by 2028. By 2030, Kamada anticipates having at least 12 marketed biosimilar products licensed from six international partners, aiming for annual revenue between $20 million and $25 million. The company also expects the commercial availability of at least two additional biosimilar products during 2027. All four launched products are approved as interchangeable with their reference biologics. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and rare disease treatments.
Kamada Ltd. announced it obtained a tax ruling from the Israel Tax Authority regarding its previously declared cash dividend of $0.17 per share, totaling approximately $9.8 million. The payment is scheduled for September 17, 2026, to shareholders of record as of August 27, 2026. Under the ruling, Nasdaq-listed shareholders residing in countries with tax treaties may apply for a reduced withholding tax rate by submitting documentation to processing agent IBI Trust Management by October 7, 2026. Israeli corporate shareholders may be eligible for an exemption from withholding tax. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and marketed products for rare conditions.
Kamada Ltd. declared a cash dividend of $0.17 per share, totaling approximately $9.8 million, consistent with its existing dividend policy. The payment is scheduled for September 17, 2026, to shareholders of record as of August 27, 2026. This announcement accompanies the company's report of record-high revenue and profitability for the first six months of 2026. Kamada Ltd. operates in the biopharmaceutical industry, specializing in specialty plasma-derived therapies and marketed products for rare conditions.